Aveanna Healthcare (AVAH) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Q1 2026 results expected: Aveanna will likely report Q1 2026 earnings before the market opens on Thursday, May 14, with analysts forecasting EPS $0.13 and revenue of about $613.22 million; the earnings call is set for 10:00 AM ET.
• Valuation and leverage: Shares opened at $6.76 (12‑month range $3.73–$10.32) with a market cap of $1.47B and a PE of 6.63, but the company carries high leverage (debt‑to‑equity 6.62) and 50/200‑day moving averages of $6.75/$8.04.
• Insider selling and analyst stance: Insiders have been net sellers — the CEO sold 173,225 shares on Feb. 19 and insiders sold 738,957 shares (~$5.46M) over the last 90 days — while the consensus rating is a Moderate Buy with a $10.25 price target.

Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $613.2190 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 10:00 AM ET.

Aveanna Healthcare Price Performance

Shares of AVAH stock opened at $6.76 on Thursday. Aveanna Healthcare has a 12 month low of $3.73 and a 12 month high of $10.32. The company has a market capitalization of $1.47 billion, a PE ratio of 6.63 and a beta of 1.93. The firm's 50-day moving average is $6.75 and its two-hundred day moving average is $8.04. The company has a debt-to-equity ratio of 6.62, a current ratio of 1.32 and a quick ratio of 1.32.

Analyst Ratings Changes

A number of brokerages have weighed in on AVAH. Raymond James Financial upgraded shares of Aveanna Healthcare from an "outperform" rating to a "strong-buy" rating and set a $13.00 price objective for the company in a report on Friday, March 20th. Zacks Research cut shares of Aveanna Healthcare from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 3rd. UBS Group lifted their price objective on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the company a "neutral" rating in a report on Thursday, January 15th. Barclays dropped their price objective on shares of Aveanna Healthcare from $11.00 to $9.50 and set an "overweight" rating for the company in a report on Wednesday, March 25th. Finally, Truist Financial dropped their price objective on shares of Aveanna Healthcare from $9.00 to $8.00 and set a "hold" rating for the company in a report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Aveanna Healthcare currently has a consensus rating of "Moderate Buy" and a consensus price target of $10.25.

Insider Transactions at Aveanna Healthcare

In related news, CEO Jeff Shaner sold 173,225 shares of the company's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total value of $1,248,952.25. Following the completion of the sale, the chief executive officer owned 2,650,892 shares in the company, valued at $19,112,931.32. This represents a 6.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Deborah Stewart sold 11,181 shares of the company's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total transaction of $80,615.01. Following the completion of the sale, the chief accounting officer owned 301,807 shares of the company's stock, valued at approximately $2,176,028.47. This trade represents a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 738,957 shares of company stock worth $5,458,175 over the last 90 days. Company insiders own 5.30% of the company's stock.

Hedge Funds Weigh In On Aveanna Healthcare

Several institutional investors have recently bought and sold shares of AVAH. Quantbot Technologies LP acquired a new position in Aveanna Healthcare in the 2nd quarter valued at $43,000. Oxford Asset Management LLP acquired a new position in Aveanna Healthcare in the 2nd quarter valued at $64,000. Bayesian Capital Management LP acquired a new position in Aveanna Healthcare in the 2nd quarter valued at $85,000. Jain Global LLC acquired a new position in Aveanna Healthcare in the 4th quarter valued at $102,000. Finally, Invesco Ltd. increased its stake in Aveanna Healthcare by 31.1% in the 2nd quarter. Invesco Ltd. now owns 20,006 shares of the company's stock valued at $105,000 after buying an additional 4,742 shares during the period. 87.96% of the stock is owned by institutional investors and hedge funds.

About Aveanna Healthcare

Aveanna Healthcare, Inc NASDAQ: AVAH is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna's offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.